Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)

Detalles Bibliográficos
Autores principales: Nakai, Hidekatsu, Matsumura, Noriomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126630/
https://www.ncbi.nlm.nih.gov/pubmed/37113737
http://dx.doi.org/10.1177/17588359231168509
_version_ 1785030296085725184
author Nakai, Hidekatsu
Matsumura, Noriomi
author_facet Nakai, Hidekatsu
Matsumura, Noriomi
author_sort Nakai, Hidekatsu
collection PubMed
description
format Online
Article
Text
id pubmed-10126630
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-101266302023-04-26 Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639) Nakai, Hidekatsu Matsumura, Noriomi Ther Adv Med Oncol Letter to the Editor SAGE Publications 2023-04-17 /pmc/articles/PMC10126630/ /pubmed/37113737 http://dx.doi.org/10.1177/17588359231168509 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Letter to the Editor
Nakai, Hidekatsu
Matsumura, Noriomi
Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)
title Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)
title_full Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)
title_fullStr Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)
title_full_unstemmed Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)
title_short Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)
title_sort comment on ‘population-adjusted indirect treatment comparison of maintenance parp inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (ther adv med oncol. 2021 sep 30;13:17588359211049639)
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126630/
https://www.ncbi.nlm.nih.gov/pubmed/37113737
http://dx.doi.org/10.1177/17588359231168509
work_keys_str_mv AT nakaihidekatsu commentonpopulationadjustedindirecttreatmentcomparisonofmaintenanceparpinhibitorwithorwithoutbevacizumabversusbevacizumabaloneinwomenwithnewlydiagnosedadvancedovariancancertheradvmedoncol2021sep301317588359211049639
AT matsumuranoriomi commentonpopulationadjustedindirecttreatmentcomparisonofmaintenanceparpinhibitorwithorwithoutbevacizumabversusbevacizumabaloneinwomenwithnewlydiagnosedadvancedovariancancertheradvmedoncol2021sep301317588359211049639

Ejemplares similares